Results 171 to 180 of about 252,949 (237)

Plain Language Summary of the Scientific opinion on welfare of horses at slaughter. [PDF]

EFSA J
europepmc   +1 more source

‘They Even Have the Capacity, but the Places Aren't Prepared to Receive Them’: Community Environment and Participation of Autistic Children in a Family‐Engaged Research Analysis

Autism Research, EarlyView.
ABSTRACT To examine the associations between community environmental barriers and support and the participation of autistic children, and to interpret these findings from the perspective of caregivers engaged as research partners. This cross‐sectional observational study employed a mixed‐methods design.
Léia Cordeiro de Oliveira, Cid André Fidelis de Paula Gomes, Gustavo Pietracatelli Janizello, Wallace Pereira Silva, Alice Soper, Monika Novak‐Pavlic, Olaf Kraus de Camargo, Soraia Micaela Silva   +7 more
wiley   +1 more source

Scientific opinion on the extension of the authorisation of use of the food additive steviol glycosides (E 960a-d) and the modification of the acceptable daily intake (ADI) for steviol. [PDF]

EFSA J
EFSA Panel on Food Additives and Flavourings (FAF), Castle L, Andreassen M, Aquilina G, Bastos ML, Boon P, Fallico B, FitzGerald R, Frutos Fernandez MJ, Grasl-Kraupp B, Gundert-Remy U, Gürtler R, Houdeau E, Kurek M, Louro H, Morales P, Passamonti S, Barat Baviera JM, Degen G, Gott D, Herman L, Leblanc JC, Moldeus P, Waalkens-Berendsen I, Wölfle D, Civitella C, Ruggeri L, Tard A, Dino B, Vermeiren S.   +29 more
europepmc   +1 more source

Harnessing plant‐based platform for low‐cost cellulosic sugar recovery from bioenergy crops

Biofuels, Bioproducts and Biorefining, EarlyView.
Abstract The price of pure cellulase enzyme for the recovery of fermentable cellulosic sugars is one of the major challenges that limit the commercialization of second‐generation biofuels and bio‐based products. This work shows a means to greatly reduce the cost of cellulases. The abundant capacity of plants to synthesize and hyperaccumulate transgenic
Shraddha Maitra, Kristen Eilts, Raunak Bansal, Stephen P. Long, Vijay Singh   +4 more
wiley   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Scientific Opinion on additional scientific data related to the safety of monacolins from red yeast rice submitted pursuant to Article 8(4) of Regulation (EC) No 1925/2006. [PDF]

EFSA J
EFSA Panel on Nutrition, Novel Foods and Food Allergens (NDA), Turck D, Bohn T, Cámara M, Castenmiller J, De Henauw S, Hirsch-Ernst KI, Jos Á, Mangelsdorf I, McNulty B, Naska A, Pentieva K, Siani A, Thies F, Matijević L, Martinez SV, Maciuk A.   +17 more
europepmc   +1 more source

Beyond the label: Rethinking off‐label drug use in paediatrics. Towards a scientifically grounded and safer future for paediatric pharmacotherapy

British Journal of Clinical Pharmacology, EarlyView.
Abstract Despite regulatory progress being made in the past two decades, off‐label drug use in paediatrics remains pervasive, with prevalence estimated between 3% and 97% of prescriptions across different clinical settings. Off‐label use—defined as prescribing outside the conditions described in the Summary of Product Characteristics (SmPC)—is often ...
Tjitske M. van der Zanden, Miriam G. Mooij, Matthijs de Hoog, Saskia N. de Wildt   +3 more
wiley   +1 more source

Re-evaluation of certain aspects of the EFSA Scientific Opinion of April 2010 on risk assessment of parasites in fishery products, based on new scientific data. Part 2. [PDF]

EFSA J
EFSA Panel on Biological Hazards (BIOHAZ), Allende A, Alvarez-Ordóñez A, Bortolaia V, Bover-Cid S, De Cesare A, Dohmen W, Guillier L, Herman L, Jacxsens L, Nauta M, Mughini-Gras L, Ottoson J, Peixe L, Perez-Rodriguez F, Skandamis P, Suffredini E, Buchmann K, Levsen A, Mattiucci S, Mladineo I, Santos MJ, Guerra B, Goudjihounde SM, Hempen M, Bolton D.   +25 more
europepmc   +1 more source

Through the lens of marketing authorization holders: experience in use of real‐world data and real‐world evidence in drug development and regulatory submissions in EU

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim The aim of this study was to assess the general and product‐specific experiences of MAHs use of RWD/RWE in medicines development and in their regulatory submissions, and to explore organizational aspects of MAHs related to RWD/RWE. Methods An electronic survey was conducted, and information collected directly from MAHs.
Sini M. Eskola, Aleksandar Gigov, Hubertus G. M. Leufkens, Andrew Bate, Marie Louise De Bruin, Helga Gardarsdottir   +5 more
wiley   +1 more source

Plain Language Summary of the Scientific opinion on welfare of horses during on-farm killing for purposes other than slaughter. [PDF]

EFSA J
europepmc   +1 more source